Doctors Without Borders coordinator describes the hunger crisis in Gaza
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
At least 37 killed, 270 injured while seeking aid in Northern Gaza: Hospital
At least 37 people were killed and 270 were injured while seeking aid in Northern Gaza near the Zikim crossing, according to the director of Gaza's Al-Shifa Hospital. The Israel Defense Forces did not immediately respond to ABC News' request for comment. MORE: A famine hasn't been declared in Gaza, but that may not matter, experts say This comes as gut-wrenching images emerge of malnourished children suffering amid the lack of food and other aid in Gaza. An increasing number of deaths due to malnutrition have been reported. According to the Hamas-run Gaza Ministry of Health, seven people died of hunger over a 24-hour period on Wednesday, bringing the total number of deaths from famine to 154 since Oct. 7, 2023, including 89 children. MORE: Trump suggests US will help with Gaza aid as Europeans join effort This is a developing story. Please check back for updates.
Yahoo
2 hours ago
- Yahoo
GE HealthCare Core Operating Margin Faces Tariffs Heat, Raises Annual Outlook
On Wednesday, GE HealthCare (NYSE:GEHC) reported second-quarter 2025 adjusted earnings of $1.06 per share, which beat the consensus of 92 cents. It was up from $1.00 a year ago. The company reported sales of $5.01 billion, beating the consensus of $4.96 billion. Revenues increased 3% on reported and 2% on an organic basis year-over-year. Revenue growth was driven by strength in the U.S. and Europe, the Middle East, and Africa. Total company book-to-bill was 1.07 times. Total company orders increased 3% organically year-over-year. The net income margin was 9.7% versus 8.9% for the prior year, which was up 80 basis points (bps) with lower tax and interest EBIT margin was 14.6% versus 15.3%, down 80 bps, impacted by tariffs, partially offset by benefits from productivity and volume. View more earnings on GEHC GE HealthCare President and CEO Peter Arduini said, 'We were pleased with solid orders and revenue performance in the second quarter across all segments, reflecting healthy customer investment in capital equipment. We also reported strong earnings performance while leveraging our lean capabilities and demonstrating progress on tariff mitigation...' Guidance GE HealthCare raises its fiscal 2025 adjusted earnings from $3.90-$4.10 per share to $4.43-$4.63 per share compared to the consensus of $4.07. The earnings outlook includes approximately 45 cents of tariff impact. Increased 2025 full-year guidance, reflective of healthy capital investment trends, operational execution, and changes in tariff rates. Adjusted EBIT margin of 15.2%-15.4%, reflecting a decline of 110 bps to 90 bps versus the 2024 Adjusted EBIT margin of 16.3%; this compares to the previous Adjusted EBIT margin guidance of 14.2%-14.4%. The company forecasts Free cash flow of at least $1.4 billion; this compares to previous Free cash flow guidance of at least $1.2 billion. Price Action: GEHC stock is down 7.53% at $71.87 at the last check Wednesday. Read Next:Photo by PixelBiss via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article GE HealthCare Core Operating Margin Faces Tariffs Heat, Raises Annual Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone
Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that it achieved the over 50% enrollment milestone in its Phase 2a trial of Namodenoson for pancreatic cancer. The Phase 2a study is a multicenter, open-label trial enrolling patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one line of prior therapy. The study is evaluating the safety (primary endpoint), clinical activity, and pharmacokinetics (PK) of Namodenoson in this patient population. Participants receive oral Namodenoson at a dose of 25 mg, administered twice daily in continuous 28-day cycles. Patients are regularly monitored for safety, and to date, Namodenoson has demonstrated a favorable safety profile. The study is led by Prof. Salomon Stemmer, a renowned oncologist and key opinion leader at the Davidoff Center, Rabin Medical Center, Israel. 'This milestone reflects the strong interest among both investigators and patients in exploring Namodenoson as a potential treatment for one of the deadliest and most aggressive cancers,' stated Pnina Fishman, Ph.D., Chief Scientific Officer of Can-Fite BioPharma. 'We are encouraged by the pace of enrollment and remain committed to advancing Namodenoson as a much-needed therapeutic option for patients with pancreatic cancer.' Namodenoson is a highly selective A3 adenosine receptor (A3AR) agonist, which has shown a compelling safety profile and demonstrated anti-tumor activity in preclinical pancreatic cancer models. The drug is also being evaluated in clinical trials for advanced liver cancer. Namodenoson has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: Forward-Looking Statements This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are 'forward looking statements'. Forward-looking statements can be identified by the use of forward-looking words such as 'believe,' 'expect,' 'intend,' 'plan,' 'may,' 'should' or 'anticipate' or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the 'Risk Factors' section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Can-Fite BioPharma Motti Farbstein info@ +972-3-9241114
